Unfolding and aggregation of transthyretin by the truncation of 50 N-terminal amino acids

Proteins: Structure, Function and Genetics

Volumn 72, Issue 1, 2008, Pages 261-269

  Mizuguchi, Mineyuki ^a   Hayashi, Ayumi ^a   Takeuchi, Makoto ^a   Dobashi, Mizuki ^a   Mori, Yoshihiro ^a   Shinoda, Hiroyuki ^a   Aizawa, Tomoyasu ^b   Demura, Makoto ^b   Kawano, Keiichi ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Aggregation; Amyloid; Amyloid disease; Transthyretin; Unfolding

Indexed keywords

AMINO ACID; PREALBUMIN;

AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; CIRCULAR DICHROISM; CONFORMATION; DELETION MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; WILD TYPE;

AMINO ACIDS; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; FLUORESCENCE; MICROSCOPY, ATOMIC FORCE; MUTANT PROTEINS; PREALBUMIN; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ANALYSIS, PROTEIN; SEQUENCE DELETION; THIAZOLES; TIME FACTORS;

EID: 44949185533     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21919     Document Type: Article

References (66)

1. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959;183:1202-1203.
2. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest 1968;47:924-933.
3. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 1968;16:673-677.
4. Lansbury PT. In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry 1992;31:6865-6870.
5. Glenner GG. Amyloid deposits and amyloidosis. The β-fibrilloses (first of two parts). N Engl J Med 1980;302:1283-1292.
6. Felding P, Fex G. Cellular origin of prealbumin in the rat. Biochim Biophys Acta 1982;716:446-449.
7. Kato M, Kato K, Blaner WS, Chertow BS, Goodman DS. Plasma and cellular retinoid-binding proteins and transthyretin (prealbumin) are all localized in the islets of Langerhans in the rat. Proc Natl Acad Sci USA 1985;82:2488-2492.
8. Liddle CN, Reid WA, Kennedy JS, Miller ID, Horne CH. Immunolocalization of prealbumin: distribution in normal human tissue. J Pathol 1985;146:107-113.
9. Herbert J, Wilcox JN, Pham KT, Fremeau RT, Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, Roberts JL, Schon EA. Transthyretin: a choroids plexus-specific transport protein in human brain. The 1986 S Weir Mitchell award. Neurology 1986;36:900-911.
10. Jacobsson B. In situ localization of transthyretin-m RNA in the adult human liver, choroid plexus and pancreatic islets and in endocrine tumors of the pancreas and gut. Histochemistry 1989;91:299-304.
11. Kanda Y, Goodman DS, Canfield RE, Morgan FJ. The amino acid sequence of human plasma prealbumin. J Biol Chem 1974;249:6796-6805.
12. Dickson PW, Schreiber G. High levels of messenger RNA for transthyretin (prealbumin) in human choroid plexus. Neurosci Lett 1986;66:311-315.
13. Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, Segal MB. Thyroxine transport from blood to brain via transthyretin synthesis in choroids plexus. Am J Physiol 1990;258:R338-R345.
14. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 1993;90:2375-2379.
15. Gaetani S, Bellovino D, Apreda M, Devirgiliis C. Hepatic synthesis, maturation and complex formation between retinol-binding protein and transthyretin. Clin Chem Lab Med 2002;40:1211-1220.
16. Blake CC, Geisow MJ, Oatley SJ, Rerat B, Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978;121:339-356.
17. Hamilton JA, Benson MD. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001;58:1491-1521.
18. Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968;47:2025-2044.
19. Peterson PA. Studies on the interaction between prealbumin, retinol-binding protein, and vitamin A. J Biol Chem 1971;246:44-49.
20. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995;268:1039-1041.
21. Cornwell GG, III, Sletten K, Olofsson BO, Johansson B, Westermark P. Prealbumin: its association with amyloid. J Clin Pathol 1987;40:226-231.
22. Westermark P, Sletten K, Johansson B, Cornwell GG, III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843-2845.
23. Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-521.
24. Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis. Hungarian type, with mutant transthyretin (TTR Asp18Gly) Neurology 1996;47:1562-1567.
25. Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, Wisniewski T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 1996;148:361-366.
26. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-473.
27. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretintype amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-1007.
28. Connors LH, Yamashita T, Yazaki M, Skinner M, Benson MD. A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid 2004;11:61-66.
29. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000.
30. Andersson K, Olofsson A, Nielsen EH, Svehag SE, Lundgren E. Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem Biophys Res Commun 2002;294:309-314.
31. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-2822.
32. Matsubara K, Mizuguchi M, Igarashi K, Shinohara Y, Takeuchi M, Matsuura A, Saitoh T, Mori Y, Shinoda H, Kawano K. Dimeric transthyretin variant assembles into spherical neurotoxins. Biochemistry 2005;44:3280-3288.
33. Hou X, Parkington HC, Coleman HA, Mechler A, Martin LL, Aguilar MI, Small DH. Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J Neurochem 2007;100:446-457.
34. Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat 1995;5:191-196.
35. Sletten K, Westermark P, Natvig JB. Senile cardiac amyloid is related to prealbumin. Scand J Immunol 1980;12:503-506.
36. Cornwell GG, III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618-623.
37. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-8660.
38. McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 1993;32:12119-12127.
39. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995;34:13527-13536.
40. Sebastiao MP, Saraiva MJ, Damas AM. The crystal structure of amyloidogenic Leu55->Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J Biol Chem 1998;273:24715-24722.
41. Lashuel HA, Wurth C, Woo L, Kelly JW. The most pathogenic transthyretin variant. L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999;38:13560-13573.
42. Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 2001;98:14943-14948.
43. Cardoso I, Goldsbury CS, Muller SA, Olivieri V, Wirtz S, Damas AM, Aebi U, Saraiva MJ. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 2002;317:683-695.
44. Shinohara Y, Mizuguchi M, Matsubara K, Takeuchi M, Matsuura A, Aoki T, Igarashi K, Nagadome H, Terada Y, Kawano K. Biophysical analyses of the transthyretin variants. Tyr114His and Tyr116Ser, associated with familial amyloidotic polyneuropathy. Biochemistry 2003;42:15053-15060.
45. Takeuchi M, Mizuguchi M, Kouno T, Shinohara Y, Aizawa T, Demura M, Mori Y, Shinoda H, Kawano K. Destabilization of transthyretin by pathogenic mutations in the DE loop. Proteins 2007;66:716-725.
46. Kingsbury JS, Theberge R, Karbassi JA, Lim A, Costello CE, Connors LH. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry. Anal Chem 2007;79:1990-1998.
47. Terry CJ, Damas AM, Oliveira P, Saraiva MJ, Alves IL, Costa PP, Matias PM, Sakaki Y, Blake CC. Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J 1993;12:735-741.
48. Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993;12:743-748.
49. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996;35:6470-6482.
50. Cornwell GG, III, Sletten K, Johansson B, Westermark P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem Biophys Res Commun 1988;154:648-653.
51. Gustavsson A, Jahr H, Tobiassen R, Jacobson DR, Sletten K, Westermark P. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest 1995;73:703-708.
52. Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003;10:48-54.
53. Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005;206:224-232.
54. Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 1989;177:244-249.
55. Klunk WE, Pettegrew JW, Abraham DJ. Quantitative evaluation of congo red binding to amyloid-like proteins with a β-pleated sheet conformation. J Histochem Cytochem 1989;37:1273-1281.
56. Matsubara K, Mizuguchi M, Kawano K. Expression of a synthetic gene encoding human transthyretin in Escherichia coli. Protein Expr Purif 2003;30:55-61.
57. Schormann N, Murrell JR, Benson MD. Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid 1998;5:175-187.
58. Liu K, Cho HS, Lashuel HA, Kelly JW, Wemmer DE. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat Struct Biol 2000;7:754-757.
59. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999;19:8876-8884.
60. De Lucia R, Mauro A, Di Scapio A, Buffo A, Mortara R, Orsi L, Schiffer D. A new mutation on the transthyretin gene (Ser112 to Ile) causes an amyloid neuropathy with severe cardiac impairment. Clin Neuropathol 1993;12:S44.
61. Jacobson DR, McFarlin DE, Kane I, Buxbaum JN. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 1992;89:353-356.
62. Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983;116:880-888.
63. Saraiva MJ, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy. Portuguese type definition of molecular abnormality in transthyretin (prealbumin) J Clin Invest 1984;74:104-119.
64. Liu K, Kelly JW, Wemmer DE. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J Mol Biol 2002;320:821-832.
65. Pras M, Prelli F, Franklin EC, Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci USA 1983;80:539-542.
66. Westermark P, Sletten K, Olofsson BO. Prealbumin variants in the amyloid fibrils of Swedish familial amyloidotic polyneuropathy. Clin Exp Immunol 1987;69:695-701.